http://www.novonordisk.com/press/se...e9f-9292-fe52a38e1f10&sShowLanguageCode=en-GB
New data from the A1chieve® study, published today in the journal Diabetes Research and Clinical Practice, show that type 2 diabetes patients can significantly improve their blood glucose control with a low occurrence of low blood sugar (hypoglycaemia). The study showed that before treatment with a Novo Nordisk insulin analogue was initiated, the average blood glucose control (HbA1c) among the 66,726 study participants was 9.5%, which is well above the internationally recognised target of 7%.
New data from the A1chieve® study, published today in the journal Diabetes Research and Clinical Practice, show that type 2 diabetes patients can significantly improve their blood glucose control with a low occurrence of low blood sugar (hypoglycaemia). The study showed that before treatment with a Novo Nordisk insulin analogue was initiated, the average blood glucose control (HbA1c) among the 66,726 study participants was 9.5%, which is well above the internationally recognised target of 7%.
